Compare FOFO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOFO | CMMB |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 19.9M |
| IPO Year | 2025 | 2023 |
| Metric | FOFO | CMMB |
|---|---|---|
| Price | $2.15 | $2.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 5.2K | ★ 98.2K |
| Earning Date | 03-13-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $11.09 | $67.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $1.35 |
| 52 Week High | $68.00 | $3.55 |
| Indicator | FOFO | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 72.94 |
| Support Level | $1.79 | $1.49 |
| Resistance Level | $2.70 | $2.86 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 6.38 | 75.03 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their business and investment objectives. Its business consists of two main business lines: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting and Regulatory compliance and governance consulting, and the asset management services, including fund subscription and fund management services.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.